Sports doping: Emerging designer and therapeutic B2-agonists

Beta2-adrenergic agonists, or ß2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptom-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of ß2-agonists is prohibited in sports by the World Anti-Doping A...

Full description

Saved in:
Bibliographic Details
Published inClinica chimica acta Vol. 425
Main Authors Fragkaki, A.G, Georgakopoulos, C, Sterk, S.S, Nielen, M.W.F
Format Journal Article
Published 2013
Subjects
2-dimensional gas-chromatography
acting beta-adrenoreceptor agonists
beta-adrenergic agonists
chromatography-mass spectrometry
developed bronchodilati
molecularly imprinted polymers
obstructive pulmonary-disease
performance liquid-chromatography
Online AccessGet full text

Cover

More Information
Summary:Beta2-adrenergic agonists, or ß2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptom-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of ß2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel ß2-agonists molecules either by modifying the molecule of known ß2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging ß2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.
ISSN:0009-8981
1873-3492